358 related articles for article (PubMed ID: 28488110)
1. Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting.
Contursi A; Sacco A; Grande R; Dovizio M; Patrignani P
Cell Mol Life Sci; 2017 Oct; 74(19):3491-3507. PubMed ID: 28488110
[TBL] [Abstract][Full Text] [Related]
2. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
3. Use of antiplatelet agents in sepsis: a glimpse into the future.
Akinosoglou K; Alexopoulos D
Thromb Res; 2014 Feb; 133(2):131-8. PubMed ID: 24103487
[TBL] [Abstract][Full Text] [Related]
4. The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy.
Warner TD; Armstrong PC; Chan MV; Knowles RB
Expert Rev Hematol; 2016 Mar; 9(3):223-5. PubMed ID: 26822235
[No Abstract] [Full Text] [Related]
5. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.
Fox SC; May JA; Johnson A; Hermann D; Strieter D; Hartman D; Heptinstall S
Platelets; 2013; 24(5):392-400. PubMed ID: 22866894
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of the antiplatelet effect of aspirin.
Würtz M; Kristensen SD; Hvas AM; Grove EL
Curr Pharm Des; 2012; 18(33):5294-308. PubMed ID: 22724416
[TBL] [Abstract][Full Text] [Related]
7. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells.
Guillem-Llobat P; Dovizio M; Bruno A; Ricciotti E; Cufino V; Sacco A; Grande R; Alberti S; Arena V; Cirillo M; Patrono C; FitzGerald GA; Steinhilber D; Sgambato A; Patrignani P
Oncotarget; 2016 May; 7(22):32462-77. PubMed ID: 27074574
[TBL] [Abstract][Full Text] [Related]
8. Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin.
Mousa SA; Forsythe M; Bozarth J; Jin F; Confalone PN
Coron Artery Dis; 2000 Oct; 11(7):563-70. PubMed ID: 11023245
[TBL] [Abstract][Full Text] [Related]
9. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
[TBL] [Abstract][Full Text] [Related]
10. Platelet receptors as therapeutic targets: Past, present and future.
Jamasbi J; Ayabe K; Goto S; Nieswandt B; Peter K; Siess W
Thromb Haemost; 2017 Jun; 117(7):1249-1257. PubMed ID: 28597906
[TBL] [Abstract][Full Text] [Related]
11. Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
Cooke NM; Spillane CD; Sheils O; O'Leary J; Kenny D
BMC Cancer; 2015 Sep; 15():627. PubMed ID: 26353776
[TBL] [Abstract][Full Text] [Related]
12. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents.
Xu XR; Yousef GM; Ni H
Blood; 2018 Apr; 131(16):1777-1789. PubMed ID: 29519806
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological control of platelet function.
Clutton P; Folts JD; Freedman JE
Pharmacol Res; 2001 Oct; 44(4):255-64. PubMed ID: 11592859
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological approaches to studying platelet function: an overview.
Hourani SM
Methods Mol Biol; 2004; 273():73-86. PubMed ID: 15308794
[No Abstract] [Full Text] [Related]
16. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
17. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes.
Schrottmaier WC; Kral JB; Badrnya S; Assinger A
Thromb Haemost; 2015 Aug; 114(3):478-89. PubMed ID: 25904241
[TBL] [Abstract][Full Text] [Related]
18. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
[TBL] [Abstract][Full Text] [Related]
19. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation.
Philipose S; Konya V; Sreckovic I; Marsche G; Lippe IT; Peskar BA; Heinemann A; Schuligoi R
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2416-23. PubMed ID: 21071691
[TBL] [Abstract][Full Text] [Related]
20. The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils.
Taylor ML; Ilton MK; Misso NL; Watkins DN; Hung J; Thompson PJ
Br J Clin Pharmacol; 1998 Aug; 46(2):139-45. PubMed ID: 9723822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
